TITLE

Curcumin Down-Regulates DNA Methyltransferase 1 and Plays an Anti-Leukemic Role in Acute Myeloid Leukemia

AUTHOR(S)
Yu, Jianhua; Peng, Yong; Wu, Lai-Chu; Xie, Zhiliang; Deng, Youcai; Hughes, Tiffany; He, Shun; Mo, XiaoKui; Chiu, Ming; Wang, Qi-En; He, Xiaoming; Liu, Shujun; Grever, Michael R.; Chan, Kenneth K.; Liu, Zhongfa
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Bioactive components from dietary supplements such as curcumin may represent attractive agents for cancer prevention or treatment. DNA methylation plays a critical role in acute myeloid leukemia (AML) development, and presents an excellent target for treatment of this disease. However, it remains largely unknown how curcumin, a component of the popular Indian spice turmeric, plays a role in DNA hypomethylation to reactivate silenced tumor suppressor genes and to present a potential treatment option for AML. Here we show that curcumin down-regulates DNMT1 expression in AML cell lines, both in vitro and in vivo, and in primary AML cells ex vivo. Mechanistically, curcumin reduced the expression of positive regulators of DNMT1, p65 and Sp1, which correlated with a reduction in binding of these transcription factors to the DNMT1 promoter in AML cell lines. This curcumin-mediated down-regulation of DNMT1 expression was concomitant with p15INK4B tumor suppressor gene reactivation, hypomethylation of the p15INK4B promoter, G1 cell cycle arrest, and induction of tumor cell apoptosis in vitro. In mice implanted with the human AML MV4–11 cell line, administration of curcumin resulted in remarkable suppression of AML tumor growth. Collectively, our data indicate that curcumin shows promise as a potential treatment for AML, and our findings provide a basis for future studies to test the clinical efficacy of curcumin – whether used as a single agent or as an adjuvant – for AML treatment.
ACCESSION #
87624130

 

Related Articles

  • High DNA Methyltransferase DNMT3B Levels: A Poor Prognostic Marker in Acute Myeloid Leukemia. Hayette, Sandrine; Thomas, Xavier; Jallades, Laurent; Chabane, Kaddour; Charlot, Carole; Tigaud, Isabelle; Gazzo, Sophie; Morisset, Stéphane; Cornillet-Lefebvre, Pascale; Plesa, Adriana; Huet, Sarah; Renneville, Aline; Salles, Gilles; Nicolini, Franck Emmanuel; Magaud, Jean-Pierre; Michallet, Mauricette // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    It has been recently shown that DNA methyl transferase overexpression is correlated with unfavourable prognosis in human malignancies while methylation deregulation remains a hallmark that defines acute myeloid leukemia (AML). The oncogenic transcription factor EVI1 is involved in methylation...

  • Regression Analysis of Combined Gene Expression Regulation in Acute Myeloid Leukemia. Li, Yue; Liang, Minggao; Zhang, Zhaolei // PLoS Computational Biology;Oct2014, Vol. 10 Issue 10, p1 

    Gene expression is a combinatorial function of genetic/epigenetic factors such as copy number variation (CNV), DNA methylation (DM), transcription factors (TF) occupancy, and microRNA (miRNA) post-transcriptional regulation. At the maturity of microarray/sequencing technologies, large amounts of...

  • CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia. Hájková, Hana; Fritz, Markus Hsi-Yang; Haškovec, Cedrik; Schwarz, Jiří; Šálek, Cyril; Marková, Jana; Krejčík, Zdenĕk; Merkerová, Michaela Dostálová; Kostečka, Arnošt; Vostrý, Martin; Fuchs, Ota; Michalová, Kyra; Cetkovský, Petr; Beneš, Vladimír // Journal of Hematology & Oncology;2014, Vol. 7 Issue 1, p1 

    Background Studying DNA methylation changes in the context of structural rearrangements and point mutations as well as gene expression changes enables the identification of genes that are important for disease onset and progression in different subtypes of acute myeloid leukemia (AML) patients....

  • Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1. Morenos, Leah; Chatterton, Zac; Ng, Jane L.; Halemba, Minhee S.; Parkinson-Bates, Mandy; Mechinaud, Francoise; Elwood, Ngaire; Saffery, Richard; Wong, Nicholas C. // Molecular Cancer;2014, Vol. 13 Issue 1, p1 

    Background Acute Myeloid Leukaemia (AML) is a highly heterogeneous disease. Studies in adult AML have identified epigenetic changes, specifically DNA methylation, associated with leukaemia subtype, age of onset and patient survival which highlights this heterogeneity. However, only limited DNA...

  • Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Tsao, Twee; Shi, Yuexi; Kornblau, Steven; Lu, Hongbo; Konoplev, Sergej; Antony, Ansu; Ruvolo, Vivian; Qiu, Yi; Zhang, Ninaxiang; Coombes, Kevin; Andreeff, Michael; Kojima, Kensuke; Konopleva, Marina // Annals of Hematology;Dec2012, Vol. 91 Issue 12, p1861 

    DNA methylation and BLC-2 are potential therapeutic targets in acute myeloid leukemia (AML). We investigated pharmacologic interaction between the DNA methyltransferase inhibitor 5-azacytidine (5-AZA) and the BCL-2 inhibitor ABT-737. Increased BCL-2 expression determined by reverse phase protein...

  • Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia. Sonnet, Miriam; Claus, Rainer; Becker, Natalia; Zucknick, Manuela; Petersen, Jana; Lipka, Daniel B.; Oakes, Christopher C.; Andrulis, Mindaugas; Lier, Amelie; Milsom, Michael D.; Witte, Tania; Lei Gu; Kim-Wanner, Soo-Zin; Schirmacher, Peter; Wulfert, Michael; Gattermann, Norbert; Lübbert, Michael; Rosenbauer, Frank; Rehli, Michael; Bullinger, Lars // Genome Medicine;2014, Vol. 6 Issue 4, p91 

    Background Aberrant DNA methylation is frequently found in human malignancies including acute myeloid leukemia (AML). While most studies focus on later disease stages, the onset of aberrant DNA methylation events and their dynamics during leukemic progression are largely unknown. Methods We...

  • 5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Curik, N; Burda, P; Vargova, K; Pospisil, V; Belickova, M; Vlckova, P; Savvulidi, F; Necas, E; Hajkova, H; Haskovec, C; Cermak, J; Krivjanska, M; Trneny, M; Laslo, P; Jonasova, A; Stopka, T // Leukemia (08876924);Aug2012, Vol. 26 Issue 8, p1804 

    Epigenetic 5-azacitidine (AZA) therapy of high-risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) represents a promising, albeit not fully understood, approach. Hematopoietic transcription factor PU.1 is dynamically regulated by upstream regulatory element (URE), whose...

  • The Transcriptome Study of Subtype M2 Acute Myeloblastic Leukemia. Wu, A-yang; Yang, Hui-cong; Lin, Cong-meng; Wu, Bi-de; Qu, Qi-shui; Zheng, Yuan-hai; Wei, Hua; Mei, Xu-qiao; Zeng, Zhen-hua; Ma, Xu-dong // Cell Biochemistry & Biophysics;Jul2015, Vol. 72 Issue 3, p653 

    Our objective is to explore the tumor-specific mutated genes by transcriptome sequencing of patients with acute myeloblastic leukemia. 96 patients with subtype M2 acute myeloid leukemia (AML), admitted during January 2007 to January 2012, were selected. Bone marrow and peripheral blood samples...

  • Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells.  // Journal of Experimental & Clinical Cancer Research (17569966);2012, Vol. 31 Issue 1, p27 

    The article offers information on the study conducted by the authors related to curcumin, that decreases the expression of Wilms tumor 1 (WT1) by upregulation of miR-15a and miR-16-1 in leukemic cells. It states that curcumin, a naturally occurring flavinoid and proapoptotic compound derived...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics